Home » Education and Training » Scripps Genomics Primer » Genomics 101: A Primer
| Key word / concept | Slide set | Slide # |
|---|---|---|
| 1000 Genomes Project | Pharmacogenomics | 17 |
| Allele | Genotyping | 2 |
| Cancer | ||
| - Gene pathways | Cancer Genomics | 28 |
| ---- APC/Hedgehog | Cancer Genomics | 30 |
| ---- Apoptosis | Cancer Genomics | 30 |
| ---- Glioma-associated | Cancer Genomics | 31 |
| ---- Hypoxia-inducible factor-1 | Cancer Genomics | 29 |
| ---- PI3K | Cancer Genomics | 32 |
| ---- Receptor tyrosine kinase | Cancer Genomics | 29 |
| ---- Retinoblastoma | Cancer Genomics | 31 |
| ---- SMAD | Cancer Genomics | 32 |
| - Identifying cancer genes | Cancer Genomics | 15-18 |
| - Mutations | Cancer Genomics | |
| ---- Cancer Gene Census | Cancer Genomics | 21-22 |
| ---- Categories | Cancer Genomics | 23 |
| ---- Gene types | ||
| -------- Proto oncogenes | Cancer Genomics | 12 |
| -------- Tumor suppressor genes | Cancer Genomics | 13 |
| -------- Stability/caretaker genes | Cancer Genomics | 14 |
| ---- Inherited | ||
| -------- oncogenes | Cancer Genomics | 37 |
| -------- tumor suppressor genes | Cancer Genomics | 34-36 |
| ---- Somatic (by pathway) | Cancer Genomics | 38-41 |
| - Properties of cancer cells | Cancer Genomics | 6-9 |
| - Types | Cancer Genomics | 5 |
| ---- Breast | Cancer Genomics | 24 |
| ---- Colorectal | Cancer Genomics | 25 |
| ---- Prostate | 26 | |
| - Validating cancer genes | 19 | |
| Cancer Genome Atlas | Pharmacogenomics | 18 |
| Cancer Genomics | 20 | |
| Cells | ||
| - general | Basics | 2 |
| - somatic cell | DNA and Heredity | 9 |
| - germline cell | DNA and Heredity | 9 |
| - stem cell | DNA and Heredity | 9 |
| Chromosomes | ||
| - general | DNA and Heredity | 2 |
| - abnormalities. | ||
| ---- cause | Mutations | 8-9 |
| ---- numerical | Mutations | 4-5 |
| ---- risk factors | Mutations | 10 |
| ---- structural | Mutations | 4-6 |
| DNA | ||
| - composition | Basics | 3 |
| - markers | Genotyping | 2 |
| - types, | ||
| ---- autosomal | DNA and Heredity | 4 |
| ---- X chromosome | DNA and Heredity | 5 |
| ---- Y chromosome | DNA and Heredity | 6 |
| ---- Mitochondrial | DNA and Heredity | 7 |
| Genes | ||
| - coding | Basics | 4 |
| - non-coding | Basics | 4 |
| Gene testing | ||
| - available tests | Gene Testing | 6 |
| - definition | Gene Testing | 2 |
| - disease prediction | Gene Testing | 7-8 |
| - ethical concerns | Genetics in Society | |
| - genetic risk | Gene Testing | 9 |
| - issues | Gene Testing | 5 |
| - pros & cons | Gene Testing | 4 |
| - reasons for | Gene Testing | 3 |
| Genetic Legislation | ||
| - Genetic Information Nondiscrimination Act (GINA) | Genetics in Society | 3-4 |
| - Genomics and Personalized Medicine Act | ||
| - Laboratory Test Improvement Act | Genetics in Society | 5 |
| - Newborn Screening Saves Lives Act | ||
| Genetics in Society | 6 | |
| Genetics in Society | 7 | |
| Genotype | ||
| - definition | Genotyping | 4 |
| - assays, | ||
| ---- PCR | Genotyping | 11 |
| ---- DNA fragment analysis | Genotyping | 11 |
| ---- Allele-specific probes | Genotyping | 12 |
| ---- DNA sequencing | Genotyping | 12 |
| ---- DNA microarrays/beads | Genotyping | 13 |
| GWAS | ||
| - benefit to public | GWAS | 5 |
| - definition | GWAS | 3 |
| - interpretation | GWAS | 9 |
| - methodology | GWAS | 7-8 |
| - purpose | GWAS | 4 |
| - use in disease | GWAS | 6 |
| Haplotype | Genotyping | 6-8 |
| International HapMap Project | GWAS | 2 |
| Meiosis | Mutations | 8 |
| Mitosis | Mutations | 8 |
| Mutation | ||
| - chromosomal abnormalities | Mutations | 4-6 |
| - types, | ||
| ---- deletion | Mutations | 7 |
| ---- duplication | Mutations | 7 |
| ---- inversion | Mutations | 7 |
| ---- translocation | Mutations | 7 |
| ---- rings | Mutations | 7 |
| Omics | ||
| - cascade | ‘Omics’ | 3 |
| - comprehensive ‘omics’ | ‘Omics’ | 5 |
| - definitions | ‘Omics’ | 4 |
| Pharmacogenetics Knowledge Base | Pharmacogenomics | 18 |
| Pharmacogenomics | ||
| - application in drug development | Pharmacogenomics | 8 |
| - ethical concerns | Genetics in Society | 9-10 |
| - evolution | Pharmacogenomics | 2-7 |
| - examples, | ||
| ---- CYP2C19 | Pharmacogenomics | 14-15 |
| ---- CACNA1C | Pharmacogenomics | 16 |
| Pharmacodynamics | Pharmacogenomics | 10-11 |
| Pharmacokinetics | Pharmacogenomics | 10-11 |
| Proteins | ||
| - structure | Basics | 5 |
| Sequencing | ||
| - exome, targeted | Sequencing | 10-13 |
| - next-generation methods, | ||
| ---- in vitro amplification | Sequencing | 7 |
| ---- parallelized screening | Sequencing | 7 |
| ---- ligation | Sequencing | 8 |
| ---- microfluidic Sanger | Sequencing | 8 |
| - next next-gen methods, | ||
| ---- hybridization | Sequencing | 9 |
| ---- mass spectrometry | Sequencing | 9 |
| ---- other, under development | Sequencing | 9 |
| - timeline | Sequencing | 3-5 |
| Single nucleotide polymorphisms | ||
| - categories, | ||
| ---- causative | Mutations | 14 |
| ---- linked | Mutations | 14 |
| - definition | Mutations | 12 |
| - in GWAS | GWAS | 8 |
| - properties | Mutations | 13 |
| - use | Genotyping | 6-9 |